Creating Impactful Deals Across Healthcare & Life science

Explore Our Expertise

2025

Strategic Divestitures for Bayer Pharma

Link

2025

Raised pre-ipo round for boat building company

Link

2022

Divested AFDIL's portfolio of brands to Lupin Limited

Link

2025

Facilitating Landmark Innovation Investments: Alveolus Bio and Shilpa Pharma

Link

2025

Strategic Brand Acquisitions: CORONA Remedies and Bayer Pharma

Link

Strategic brand divestment for Galderma

Learn more

Strategic Investment for Generic Partners (Australia) from Strides Pharma

Learn more

Advised Natural Endotech for its entry into Indian market with Patented Women-Care Product

Learn more

GCViB Advises on Licensing of Entra Health Systems’ Medical Device into the Indian Market

Learn more

GCViB Facilitates the India Launch of Unicity

Learn more

2025

GCV IB Advises on Zeus Hygia’s Series A Funding of $2.5 million from NABVENTURES

Learn more